Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20 Significant Single Agent Anti-Tumor Activity Observed With PEGPH20 in Tumor Models That Accumulate Hyaluronan Extended Half-Life of PEGPH20 Allows Continued Depletion of ...

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic First Patient Dosed With Second Roche Biologic Formulated With Halozyme's Recombinant Enzyme Technology Halozyme to Receive Milestone Payment SAN DIEGO, Jan....

Halozyme to Present At J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 8, 2009 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the...